Skip to Content
  • Previous Rank245
  • Revenues ($M)$13,452.9
  • Revenue Percent Change9.6%
  • Profits ($M)$4,430.7
  • Profits Percent Change74.5%
  • Assets ($M)$25,288.9
  • Employees7,800

The biotechnology company discovers and manufactures treatments for autoimmune disorders and neurodegenerative diseases. It also makes and sells biosimilars of advanced biologics.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

Michel Vounatsos
CEO Title
Chief Executive Officer & Director
Health Care
HQ Location
Cambridge, Mass.
Years on Fortune 500 List10

Biogen Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$13,452.99.6%
Profits ($M)$4,430.774.5%
Assets ($M)$25,288.9-
Total Stockholder Equity ($M)$13,039.6-

Profit Ratios

Profit as % of Revenues32.9%
Profits as % of Assets17.5%
Profits as % of Stockholder Equity34.0%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)21.58
EPS % Change (from 2017)81.0%
EPS % Change (5 year annual rate)22.5%
EPS % Change (10 year annual rate)23.3%

Total Return

Total Return to Investors (2018)-5.5%
Total Return to Investors (5 year, annualized)3.1%
Total Return to Investors (10 year, annualized)21.2%